Compare Newron Pharmaceuticals SpA with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 231.49%
- Poor long term growth as Net Sales has grown by an annual rate of 48.06% and Operating profit at 29.66% over the last 5 years
- The company is Net-Debt Free
2
With ROE of 1624.07%, it has a Very Expensive valuation with a 231.72 Price to Book Value
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-28.54%
0%
-28.54%
6 Months
-5.95%
0%
-5.95%
1 Year
77.09%
0%
77.09%
2 Years
38.6%
0%
38.6%
3 Years
226.9%
0%
226.9%
4 Years
930.43%
0%
930.43%
5 Years
573.93%
0%
573.93%
Newron Pharmaceuticals SpA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
48.06%
EBIT Growth (5y)
29.66%
EBIT to Interest (avg)
-2.46
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
27.41
Sales to Capital Employed (avg)
0.48
Tax Ratio
26.17%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.64%
ROE (avg)
231.49%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
231.72
EV to EBIT
10.56
EV to EBITDA
10.50
EV to Capital Employed
36.30
EV to Sales
6.21
PEG Ratio
0.06
Dividend Yield
NA
ROCE (Latest)
343.88%
ROE (Latest)
1624.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
49.00
8.80
456.82%
Operating Profit (PBDIT) excl Other Income
25.10
-11.10
326.13%
Interest
4.10
4.70
-12.77%
Exceptional Items
-1.20
0.00
Consolidate Net Profit
15.10
-15.80
195.57%
Operating Profit Margin (Excl OI)
509.30%
-1,284.00%
179.33%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 456.82% vs 44.26% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 195.57% vs 10.23% in Dec 2023
About Newron Pharmaceuticals SpA 
Newron Pharmaceuticals SpA
Pharmaceuticals & Biotechnology
Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson’s disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.
Company Coordinates 
Company Details
Via Ludovico Ariosto 21 , BRESSO None : 20091
Registrar Details






